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ABSTRACT
Objectives: To assess the usefulness of adding PET/CT as a preoperative test for determining the extent of endometrial 
cancer and discriminating low- and high-risk patients to identify candidates for surgical staging.
Material and methods: We retrospectively reviewed 86 patients with pathologically proven endometrial cancer who 
had undergone preoperative 18F-FDG PET/CT. The prognostic relationships between PET/CT parameters and pathology 
reports were assessed.
Results: The SUVmax was significantly higher in patients with FIGO stage IB or higher compared with those with stage IA; 
for stage III–IV compared with stage I–II; and for patients with lymph node metastasis compared with those without lymph 
node metastasis. Using 6.70 as a cut-off for SUVmax, low-risk patients can be identified with a sensitivity of 92.9%.
Conclusions: PET/CT imaging can be used not only for determining malignancy and lymph node involvement but also for 
determining candidates for surgical staging with high sensitivity. 
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INTRODUCTION
Endometrial carcinoma is the most common gynaeco-
logical malignancy in developed countries, and after car-
cinoma of the uterine cervix, is the second most common 
gynaecological malignancy worldwide, with 319,600 new 
cases diagnosed in 2012 [1]. The prognosis for endometrial 
cancer is generally favourable because most patients have 
early-stage disease at the time of diagnosis [2]. The 5-year 
survival rate for endometrial cancer patients is ≥ 80% [3]. 
The main determinants of prognosis are disease stage, 
histological subtype, presence of lymph node metastasis, 
depth of myometrial invasion, and presence of cervical 
involvement [4]. The risk factors in advanced disease are 
less clear. The most widely accepted surgical staging system 
for endometrial cancer by the International Federation of 
Obstetrics and Gynaecology (FIGO) includes abdominal ex-
ploration, pelvic peritoneal cytology, hysterectomy, bilateral 
salpingo-oophorectomy, and pelvic and aortic selective 
lymphadenectomy. This system allows an accurate predic-
tion of prognosis and assists in determining the optimal 
treatment for each patient. Given the invasive nature of 
the staging process, surgeons tend to rely on a detailed 
preoperative imaging evaluation to determine appropriate 
therapeutic management [5].
18F-Fluorodeoxyglucose positron emission tomogra-
phy/computed tomography (18F-FDG PET/CT) is an imaging 
method that can be used to obtain anatomic and metabolic 
data on cancer cells in various malignancies [6–8]. Several 
studies have examined the usefulness of 18F-FDG PET/CT 
for determining the presence, stage, and aggressiveness of 
endometrial cancer [9, 10]. The standardised uptake value 
(SUV) is accepted as an indicator of tumour aggressiveness 
and a marker for metabolic changes in cancer tissues [11].
This study evaluated the use of SUVmax values and the 
diagnostic performance of FDG-PET in the preoperative 
evaluation of patients with endometrial cancer and in 
predicting recurrence in patients with endometrial cancer 
treated with surgery.
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MATERIAL AND METHODS
Patient characteristics
Patients diagnosed with endometrial cancer and re-
ferred to our Gynaecological Oncology Outpatient Clinic for 
preoperative assessment who underwent PET/CT as part of 
the preoperative evaluation were retrospectively enrolled 
in this study. The study protocol was approved by the insti-
tutional review board. Patients with a previous diagnosis of 
another malignancy, patients with postoperative follow-up 
for less than 1 year, and patients who did not undergo surgi-
cal staging for any reason were excluded from the study.
Following the preoperative evaluation, including PET/CT, 
all women underwent staging surgery including a total ab-
dominal hysterectomy and bilateral salpingo-oophorectomy, 
omentectomy, and bilateral pelvic and para-aortic lymph 
node dissection. The pelvic lymphadenectomy included the 
bilateral external iliac, obturator, common iliac, and presa-
cral nodes. The para-aortic lymphadenectomy included the 
nodal chains from the aortic bifurcation to the level of the 
left renal vein. The patients were staged according to the 
FIGO 2009 staging criteria [12]. The pathology was evaluated 
by experienced gynaecological pathologists at our institute 
who were blinded to the imaging information. The patients’ 
demographic, clinical, and survival data were obtained from 
the hospital database and patient follow-up files.
Imaging technique
All patients underwent PET/CT in the 2 weeks before 
surgery. All patients fasted for at least 6 hours before the 
PET/CT imaging. 18F-FDG (3.7 MBq/kg body weight) was 
administered antecubitally. After a 60–90-minute uptake 
period, whole-body PET/CT was performed.
The images were evaluated by a single experienced 
nuclear medicine physician. SUVmax was calculated using the 
equation SUV = A/(ID/BW), where A is the decay-corrected 
activity in tissue (in mCi per mL), ID is the injected dose of 
FDG (in mCi), and BW is the patient’s body weight (in grams).
Statistical analysis
Descriptive statistics for continuous variables are pre-
sented as the median and range. The SUVmax distribution 
in relation to clinical covariates was determined using the 
Mann-Whitney U-test on the natural logarithm of the value. 
The comparison of SUVmax values between multiple sub-
groups were performed by oneway ANOVA test followed 
by Fisher’s protected least significance difference test for 
all pairwise comparisons. Receiver operating characteristic 
(ROC) curve analysis was performed to determine the cut-off 
values of SUVmax for predicting clinical parameters. The area 
under the ROC curve (AUC) is presented as a measure of 
discrimination. In determining the optimal cut-off values, 
the Youden index was used. For all tests, p-values < 0.05 were 
considered significant. Statistical analysis was carried out 
using the Statistical Package for the Social Sciences (SPSS) 
ver. 19.0 (SPSS, Chicago, IL).
RESULTS
We enrolled 92 eligible patients in this study. Six pa-
tients were excluded from the study either due to absence 
of a detailed final pathology result or because they were 
unable to undergo surgery due to comorbid illnesses. Ulti-
mately, 86 patients with endometrial cancer were enrolled 
in the study. The mean patient age was 60.7 (range 39–84) 
years. The histopathological characteristics of the pa-
tients are summarised in Table 1. Of the patients, 74.5% 
(64 patients) had FIGO stage I and II disease. Overall, 46 of 
86 (53.4%) patients had Grade I disease, and 77.9% (67/86) 
of these had the endometrioid subtype (Table 2).
The SUVmax was significantly higher in patients with 
FIGO stage IB or higher compared to stage IA patients, with 
median values of 8.0 vs. 11.4 (p < 0.001). There was also 
a significant difference between stage III–IV and stage I–II, 
with median values of 8.7 and 12.5, respectively (p = 0.002), 
and between patients with and without lymph node me-
tastasis, with median values of 13.0 and 8.9, respectively 
(p < 0.001). Patients at low risk of extrauterine disease were 
identified using the Mayo Clinic criteria: grade 1–2 disease, 
tumour ≤ 2 cm, and myometrial invasion < 1/2. The SUVmax 
was significantly lower in the low-risk group compared 
with all other patients, with median values of 5.9 and 10.3, 
respectively (p < 0.001). In comparison, there were no 
significant differences in the SUVmax between FIGO grade 
1–2 and FIGO grade 3, or between tumour diameters > 2 cm 
and < 2 cm (p = 0.07 and p = 0.74, respectively). There was 
also no significant difference between endometrioid and 
Table 1. Histopathological characteristics of the patients
Values Percent
Age [years] Mean (range) 60.7 (39–84)
Tumour diameter Mean (range) 3.41 (0.5–8)
Myometrial 
invasion
None 10 11.6
< 1/2 40 46.5
> 1/2 36 41.9
Lymphovascular 
invasion
Positive 31 37
Negative 55 62.8
Histological type
Endometrioid 67 77.9
Mixed 8 9.3
Clear 6 7.0
Serous 3 3.5
Other 2 2.4
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Table 2. Clinicopathological characteristics of the patients
Patients 
(n) [%]
SUVmax
median 
(range)
Disease stage
1A 38 44.2 8.0 (3.0–20.2)
1B 20 23.3 9.5 (5.8–17.10)
2 6 7.0 10.0 (7.7–14.3)
3C 18 20.8 11.9 (3.9–18.7)
4 4 4.7 9.7 (12.7–22.4)
Grade
I 46 53.5 8.6 (3.0–20.2)
II 19 22.1 9.7 (4.5–16.7)
III 18 20.9 11.1 (5.6–22.4)
Tumour diameter
< 2 cm 59 68.6 7.9 (3.0–22.4)
> 2 cm 27 31.4 9.7 (3.1–18.4)
Myometrial 
invasion
None 10 11.6 8.1 (3.0–22.4)
< 1/2 40 46.5 8.95 (3.1–20.2)
> 1/2 36 41.9 10.3 (3.9–18.7)
Cervical stromal 
involvement
 No 70 81.4 8.7 (3.0 – 22.4 )
Yes 16 18.6 10.7 (7.7– 18.4)
LN metastasis
Yes 20 23.3 13.0 (3.9–18.7)
No 66 76.7 8.9 (3.0–22.4)
Risk assessment
Low 16 18.4 5.9 (3.0–11.5)
High 70 80.5 10.3 (3.10–22.4)
Table 3. Association between clinicopathological characteristics 
and SUVmax 
Variable Number SUVmaxmedian (range) p-value
FIGO stage
IA 38 8.0 (3.0–20.2)
 < 0.001
≥ IB 48 11.4 (3.9–22.4)
FIGO stage 
I–II 64 8.7 (3.0–20.2)
 0.002
III–IV 22 12.5 (3.9–22.4)
Grade
I 47 8.6 (3.0–20.2)
 0.07
II–III 39 11.0 (4.5–22.4)
Tumour diameter
< 2 cm 27 7.9 (3.0–22.4)
0.74
> 2 cm 59 9.7 (3.1–18.4)
LN metastasis
Yes 20 13.0 (3.9–18.7)
 < 0.001
No 66 8.9 (3.0–22.4)
Subtype
Endometrioid 67 9.7 (3.0–18.7)
 0.983
Non-endometrioid 19 8.4 (3.1–22.4)
Risk assessment
Low* 16 5.9 (3.0–11.5)
< 0.001
High 70 10.3 (3.1–22.4)
Mann-Whitney U-test 
*Low risk: tumour diameter < 2 cm, grade I tumour, endometrial subtype, 
myometrial invasion ≤ 1/2
Table 4. Comparison between SUVmax values and  FIGO (International 
Federation of Gynecology and Obstetrics) stage on preoperative 
assessment of primary endometrial cancer
Variable SUVmax
Stage Number Mean ± SE p-value
IA 38 8.58 ± 0.63
IB 20 10.9 ± 0.81 0.027
II 6 10.45 ± 0.91 0.258
III 18 11.63 ± 0.89 0.005
IV 4 17.67 ± 1.99 0.000
Oneway ANOVA
non-endometrioid subtypes, with median values of 9.7 and 
8.4, respectively (p = 0.983) (Table 3).
The mean SUVmax values of the primary tumour with 
preoperative assessment of the primary endometrial can-
cer for the FIGO stage are listed in Table 4. For the FIGO 
stage, the mean SUVmax level for stage IB, III and IV was 
significantly higher than that for stage I (p = 0.027, 0.005, 
0.000 respectively)
Figure 1 shows the ROC curves for discriminating low- 
and high-risk patients. The AUC was 0.830 [95% confidence 
interval (CI) 0.721–0.939]. Using 6.70 as a cut-off point, the 
sensitivity and specificity of SUVmax were 92.9% and 62.5%, 
respectively. Figure 2 shows the ROC curves for discrimi-
nating early- and advanced-stage patients. The AUC was 
0.721 (95% CI 0.593–0.850). At a cut-off of 10.45, the sen-
sitivity and specificity of SUVmax were 72.7% and 68.7%, 
respectively.
DISCUSSION
In endometrial cancer, a non-invasive, preoperative 
diagnostic method that evaluates the spread of disease 
would be useful for determining candidates for surgical 
staging while minimising costs [9]. Several preoperative 
imaging methods are used to determine the spread of dis-
ease in endometrial cancer, including ultrasonography, CT, 
and magnetic resonance imaging (MRI). However, all three 
techniques have some limitations [13]. The main prognostic 
factors in endometrial cancer are age, stage, histology, depth 
of myometrial invasion, cervical involvement, and lymph 
node metastasis [14]. Except age, all of the prognostic fac-
tors are evaluated after surgical staging. Several studies have 
evaluated the use of 18F-FDG PET for staging in endometrial 
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cancer patients. However, the main limitation of these stud-
ies and the meta-analysis of these studies is heterogenicity 
of the study population. In the current study, we wanted to 
evaluate the prognostic value of PET/CT imaging in endo-
metrial cancer patients for determining low- and high-risk 
candidates for surgical staging. We believe that patients who 
need surgical staging can be identified with a non-invasive, 
preoperative imaging method.
SUV values are used to differentiate benign and malig-
nant disease [15]. Endometrial sampling is a cost-effective 
method for detecting the primary tumour with high sensitiv-
ity and specificity [16]. A meta-analysis described the sensi-
tivity of 18F-FDG PET as suboptimal due to non-malignant 
physiological uptake of 18F-FDG in the normal endome-
trium [15]. As our results show, there is a gradual increase 
in SUVmax with stage and grade. This finding supports the 
idea of an increase in metabolic activity with an increase in 
the extent of disease. The gradual increase in SUVmax  can be 
used as an useful preoperative tool to stratified them to 
different surgical protocols based on PET/CT final results.
In 2013, the European Society for Medical Oncology 
(ESMO) separated endometrial cancer patients into three risk 
groups [17]. For the low-risk group, ESMO does not recom- 
mend lymphadenectomy based on the low probability of 
lymph node metastasis. The low sensitivity of PET/CT for 
determining lymph-node metastasis in endometrial cancer 
patients is the main shortcoming of this test as a diagnostic 
tool [15]. Omitting patients who need lymphadenectomy 
carries a risk of inadequate staging, leading to secondary 
lymphadenectomy or systematic adjuvant radiotherapy 
[18]. Discrepancy rates have been stated as up to 33% in 
some studies [19]. However, as shown in our study, the high 
sensitivity of PET/CT for discriminating high- and low-risk 
patients can be useful for determining candidates for lym-
phadenectomy. We believe that identifying low-risk patients 
preoperatively is important.
Like all other studies of the efficiency of PET/CT, our 
study has some limitations. The heterogeneity of the study 
group is one of the main limitations of our study. The rela-
tively small study group is another weakness. Nevertheless, 
the promising result at differentiating low-risk patients pre-
operatively is a new aspect of PET/CT scanning.
CONCLUSIONS
PET/CT imaging can be used not only for determin-
ing malignancy or lymph node involvement but also for 
determining candidates for surgical staging. If our findings 
are confirmed by larger studies, PET imaging will become 
a more valuable preoperative diagnostic tool.
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